NCT02546453View on ClinicalTrials.gov

Use of Specific Genetic Alteration s of Tumoral Cells Identified by the Next Generation Sequencing Techniques (NGS) to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor - NGSKids

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
Metastatic and/or High Risk Solid Tumor of Children
Interventions
BIOLOGICAL

Tumoral specific genetic alterations

A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.

BIOLOGICAL

Tumoral specific genetic alterations

Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).

Trial Locations (1)

75005

Institut Curie, Paris

All Listed Sponsors
lead

Institut Curie

OTHER

NCT02546453 - Use of Specific Genetic Alteration s of Tumoral Cells Identified by the Next Generation Sequencing Techniques (NGS) to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor - NGSKids | Biotech Hunter | Biotech Hunter